INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE;OSE Immunotherapeutics
发明人:
申请号：
EP17200006.9
公开号：
EP3299392A1
申请日:
2012.10.04
申请国别(地区):
EP
年份:
2018
代理人:
摘要：
The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7Ralpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells.The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.
